{"id":39150,"date":"2026-06-21T10:23:14","date_gmt":"2026-06-21T10:23:14","guid":{"rendered":"https:\/\/peptidepowereu.is\/?post_type=product&#038;p=39150"},"modified":"2026-06-21T11:04:04","modified_gmt":"2026-06-21T11:04:04","slug":"pe-22-28","status":"publish","type":"product","link":"https:\/\/peptidepowereu.is\/it\/pe-22-28\/","title":{"rendered":"PE-22-28"},"content":{"rendered":"<p><strong>PE-22-28<\/strong> is a <strong>synthetic seven-amino-acid peptide<\/strong> derived from the spadin sequence, a fragment of the sortilin propeptide. It is investigated for its ability to selectively block the <strong>TREK-1 potassium channel<\/strong>, a target strongly implicated in mood regulation, stress response, and neuronal plasticity in research models.<\/p>\n<p>In experimental rodent models, PE-22-28 has been observed to produce <strong>rapid antidepressant-like effects<\/strong>, with behavioral changes reported within hours rather than the weeks typical of conventional pharmacological agents. Studies describe <strong>increased hippocampal neurogenesis<\/strong>, enhanced <strong>BDNF expression<\/strong>, and improved synaptic plasticity following short-term administration.<\/p>\n<p>Additional research interest centers on PE-22-28&#8217;s <strong>cardioprotective profile<\/strong>, as TREK-1 inhibition has been linked to reduced post-ischemic injury in cardiac tissue models. Unlike its parent compound spadin, PE-22-28 demonstrates <strong>improved metabolic stability<\/strong> while preserving channel selectivity.<\/p>\n<p>Supplied as <strong>lyophilized powder<\/strong> for reconstitution, PE-22-28 is intended for in vitro assays and animal-model investigations into neuropsychiatric and cardiovascular pathways.<\/p>\n<p><strong>Clinical Status:<\/strong><br \/>\nPE-22-28 is a <strong>research peptide<\/strong> evaluated primarily in rodent behavioral and electrophysiological studies. It is not approved for medical use and remains restricted to <strong>experimental and laboratory research<\/strong>.<\/p>\n<p><strong>Evidence type:<\/strong><br \/>\nHuman RCT \u2610 | Observational \u2610 | Animal \u2714 | In vitro \u2714 | Regulatory \u2610<\/p>\n","protected":false},"excerpt":{"rendered":"<p>PE-22-28 is a synthetic seven-amino-acid peptide derived from the spadin sequence, a fragment of the sortilin propeptide. It is investigated<\/p>\n","protected":false},"featured_media":39545,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[513],"product_tag":[],"class_list":["post-39150","product","type-product","status-publish","has-post-thumbnail","product_cat-nootropics-cognitive-function-research","first","instock","shipping-taxable","purchasable","product-type-variable"],"acf":[],"_links":{"self":[{"href":"https:\/\/peptidepowereu.is\/it\/wp-json\/wp\/v2\/product\/39150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/peptidepowereu.is\/it\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/peptidepowereu.is\/it\/wp-json\/wp\/v2\/types\/product"}],"version-history":[{"count":1,"href":"https:\/\/peptidepowereu.is\/it\/wp-json\/wp\/v2\/product\/39150\/revisions"}],"predecessor-version":[{"id":39546,"href":"https:\/\/peptidepowereu.is\/it\/wp-json\/wp\/v2\/product\/39150\/revisions\/39546"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/peptidepowereu.is\/it\/wp-json\/wp\/v2\/media\/39545"}],"wp:attachment":[{"href":"https:\/\/peptidepowereu.is\/it\/wp-json\/wp\/v2\/media?parent=39150"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/peptidepowereu.is\/it\/wp-json\/wp\/v2\/product_brand?post=39150"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/peptidepowereu.is\/it\/wp-json\/wp\/v2\/product_cat?post=39150"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/peptidepowereu.is\/it\/wp-json\/wp\/v2\/product_tag?post=39150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}